Abstract
Gastric cancer is one of the most serious illnesses in the world because of its high morbidity and mortality.1 Currently, early detection and localization of gastric cancer sites are critical to decrease the mortality. However, it is a big challenge for clinicians who routinely utilize conventional white-light reflectance endoscope to accurately identify and localize early dysplasia, carcinoma in situ, and flat mucosal cancers in the stomach.2 The serum markers fail to diagnose or screen gastric cancer with sufficient sensitivity and specificity despite being helpful for monitoring response to therapy and detecting cancer recurrence. Although the radiological diagnostic tests, ionizing or nonionizing radiology, are proved to be effective for gastric cancer diagnosis, a positive result requires further histopathology examination [hematoxylin–eosin (H&E)], which could finally decide when and how to operate on the tumor. The result with H&E approach is invasive, time-consuming, and impractical as a routine screening tool for high-risk patients, and is also subjective based on the pathologist’s expertise.3 Yet accurate identification of the tumor margins is of remarkable clinical importance, in particular for the diffuse type of gastric cancer where the boundaries of the lesion can be indistinct and nests of cancerous cells may be found at a distance from the visible tumor margin. As an emerging spectroscopy and imaging modality for medical applications, hyperspectral imaging (HSI) offers great potential for noninvasive disease diagnosis and surgical guidance.4,5

This publication has 29 references indexed in Scilit: